Last Updated: August 9, 2026

Claims for Patent: 12,594,326

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,594,326

Title:	Compositions of GLP-1 peptides and preparation thereof
Abstract:	The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.
Inventor(s):	Thomas Kvistgaard Vilhelmsen, Helle Eliasen, Tue Hansen
Assignee:	Novo Nordisk AS
Application Number:	US19/071,109
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,594,326
Patent Claims:	1. A pharmaceutical composition comprising a first type and a second type of granules, wherein the first type of granules comprises at least 70% (w/w) of sodium N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC) and less than 10% (w/w) of a lubricant, and wherein the second type of granules comprises semaglutide, at least 15% (w/w) of a filler, and less than 40% (w/w) of a binder. 2. The pharmaceutical composition according to claim 1, wherein the lubricant is magnesium stearate. 3. The pharmaceutical composition according to claim 1, wherein the filler is microcrystalline cellulose. 4. The pharmaceutical composition according to claim 1, wherein the binder is povidone. 5. The pharmaceutical composition according to claim 1, wherein the first type of granules does not comprise semaglutide. 6. The pharmaceutical composition according to claim 1, wherein the second type of granules does not comprise SNAC. 7. The pharmaceutical composition according to claim 1, wherein the first type of granules does not comprise semaglutide, and wherein the second type of granules does not comprise SNAC. 8. The pharmaceutical composition according to claim 1, wherein the lubricant is magnesium stearate, wherein the filler is microcrystalline cellulose, and wherein the binder is povidone. 9. The pharmaceutical composition according to claim 8, wherein the first type of granules does not comprise semaglutide. 10. The pharmaceutical composition according to claim 8, wherein the second type of granules does not comprise SNAC. 11. The pharmaceutical composition according to claim 8, wherein the first type of granules does not comprise semaglutide, and wherein the second type of granules does not comprise SNAC.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.